Jomil

Tamsulosin Hydrochloride and Solifenacin Succinate, the active ingredients in Jomil, are an alpha‑1 adrenergic antagonist and a muscarinic antagonist presented as oral tablets for prescription use. They are indicated for the management of benign prostatic hyperplasia and overactive bladder in adult patients.

GNH USA supplies Jomil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory compliance across markets.

Jomil combines tamsulosin and solifenacin to target lower urinary tract disorders.

- Benign prostatic hyperplasia (BPH): improves urine flow and reduces prostate‑related urinary obstruction. - Overactive bladder (OAB): decreases urgency episodes and urinary frequency. - Lower urinary tract symptoms (LUTS): alleviates combined storage and voiding symptoms.

Jomil may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Dry mouth - Constipation - Abnormal ejaculation - Blurred vision

Serious or Rare Side Effects: - Orthostatic hypotension - Severe urinary retention - Allergic reactions (rash, angioedema) - Cardiac arrhythmia - Angle‑closure glaucoma - Hepatic injury

Before prescribing Jomil, clinicians should consider several safety factors.

- Renal or hepatic impairment: assess dosage and monitor function. - History of hypotension: monitor blood pressure after initiation. - Elderly patients: start at lower dose and observe for dizziness. - Concurrent use with strong CYP3A4 inhibitors: may increase solifenacin levels. - Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Jomil can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise solifenacin concentrations. - Alpha‑blocker combinations (e.g., doxazosin): may cause additive hypotension. - Strong anticholinergic agents: increase risk of severe anticholinergic effects.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic hypotension. - Warfarin: potential for altered INR, monitor coagulation. - Antidepressants with anticholinergic properties: may increase dry mouth and constipation.